Bethanechol is FDA approved to treat postoperative urinary retention, postpartum urinary retention, and overflow incontinence caused by neurogenic atony of the bladder. It is in the parasympathomimetic class of drugs. This activity reviews the indications, action, and contraindications for bethanechol as a valuable agent in managing nonobstructive urinary retention-related disorders when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent to members of the interprofessional team in the management of patients with nonobstructive urinary retention and related conditions.

**Objectives:**
- Identify the mechanism of action of bethanechol.
- Describe the adverse effects of bethanechol.
- Review the appropriate monitoring of bethanechol.
- Summarize some interprofessional team strategies for improving care coordination and communication to advance bethanechol use in the care of nonobstructive urinary retention and improve outcomes.